Surzebiclimab, the innovative therapeutic agent, appears to be the significant step in managing autoimmune conditions. It works by IL-17RA, a molecule contributing to immune responses associated with several https://caoimherfba129362.mpeblog.com/76093842/surzebiclimab-the-potential-hope-for-self-reactive-conditions